[18F]Flotufolastat PET/MRI in Patients with Suspected Prostate Cancer: Correlation with Histopathologic Biopsy Results [0.03%]
[18F]氟托菲奥斯特正电子发射断层磁共振成像/ X线计算机体层摄影在疑似前列腺癌患者中的应用及与组织病理学活检结果的相关性研究
Nicola Gabler,Sonja Kirchhoff,Andreas Sauter et al.
Nicola Gabler et al.
This retrospective analysis investigated the detection accuracy of [18F]flotufolastat ([18F]rhPSMA-7.3) PET/MRI in patients with suspected prostate cancer (PCa), read using the PRIMARY score. Performance was compared with that of multiparam...
Nuclear Medicine AI in Action: The Bethesda Report (AI Summit 2024) [0.03%]
核医学人工智能的应用：贝塞斯达报告（2024年AI峰会）
Arman Rahmim,Tyler J Bradshaw,Guido Davidzon et al.
Arman Rahmim et al.
The second Society of Nuclear Medicine and Molecular Imaging (SNMMI) AI Summit, organized by the SNMMI AI Task Force, took place in Bethesda, MD, on February 29-March 1, 2024. Bringing together various community members and stakeholders and...
Comparative PET Imaging for Radiosurgical Target Delineation in Residual Acromegaly [0.03%]
残余肢端肥大症放射外科手术靶区界定的比较PET影像学研究
Linus Hesse,Daniel Gillett,James MacFarlane et al.
Linus Hesse et al.
Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [18F]PSMA-1007 PET/CT and [18F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient Management [0.03%]
[18F]PSMA-1007 PET/CT和[18F]NaF PET/CT在中高危前列腺癌初始分期中的诊断准确性、临床分期及患者管理的头对头比较研究
Karen M Buch-Olsen,Mie H Vilstrup,Steinbjørn Hansen et al.
Karen M Buch-Olsen et al.
This study aimed to estimate the diagnostic accuracy and stage migration of [18F]PSMA-1007 PET/CT and its impact on patient management when compared with [18F]NaF PET/CT for primary staging of prostate cancer (PCa). Methods: In a substudy o...
Outcomes of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Patients with Metastatic Pheochromocytoma and Paraganglioma [0.03%]
177Lu-DOTATATE肽受体核素治疗转移性嗜铬细胞瘤和副神经节瘤的疗效分析
Gokce Belge Bilgin,Brian J Burkett,Cem Bilgin et al.
Gokce Belge Bilgin et al.
Peptide receptor radionuclide therapy (PRRT) has emerged as a promising treatment for metastatic pheochromocytoma and paraganglioma (mPPGL). This study aimed to evaluate PRRT outcomes in patients with mPPGL in a single institution. Methods:...
Peter J H Scott,Henry F VanBrocklin,Robin C Cumming et al.
Peter J H Scott et al.
The Role of Amyloid-β and Tau PET in the New Era of Alzheimer Disease Therapies [0.03%]
阿尔茨海默病治疗新时代中的淀粉样蛋白和tau PET的作用
Konstantinos Chiotis,Yingbing Wang,Renaud La Joie et al.
Konstantinos Chiotis et al.
The advent of amyloid-β (Aβ) and tau PET imaging has revolutionized Alzheimer disease (AD) research, enabling in vivo detection of hallmark pathologies and transforming both diagnosis and therapeutic development. These imaging modalities ...
The Final Frontier: Toward Transformative Insights into the Pathophysiologic Adaptations to Microgravity with Molecular Imaging [0.03%]
终极前沿：分子影像技术在微重力病理生理适应转化见解中的应用
Hossein Jadvar
Hossein Jadvar
Worldwide Potential of Radiotheranostics and the Challenges Faced by Developing Countries [0.03%]
放射治疗学的全球潜力及发展中国家面临的挑战
Akram Al-Ibraheem
Akram Al-Ibraheem
Modifiable Factors Associated with the Longitudinal Increase and Spatial Extent of Tau Pathology in Alzheimer Disease [0.03%]
与阿尔茨海默病纵向增加和Tau病理空间范围相关可改变因素
Merle C Hoenig,Verena Dzialas,Elena Doering et al.
Merle C Hoenig et al.
There are 14 modifiable factors that are associated with a significantly lower risk of dementia. We tested the interactive effect of modifiable factors, genetic determinants, and initial pathologic burden on the spatial progression and loca...